Universal prenatal hepatitis C virus (HCV) screening was found to be cost-effective and improved health outcomes in women diagnosed with HCV infection and identification of HCV exposure in neonates, according to a study published in Obstetrics & Gynecology. A research team used a stochastic microsimulation model to analyze the health outcomes and cost-effectiveness of universal…
Topline data from the Phase 3 STELLAR-4 trial showed that selonsertib, an investigational treatment for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), was not associated with a significant improvement in fibrosis without worsening of NASH. The safety and efficacy of selonsertib, an oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), was evaluated in a double-blind,…
The ACIP and CDC have approved and released 2019 recommendations for the adult immunization schedule in the US.
Women less likely to be treated than men; treatment visit, medication tied to improved 1-year outcomes.
Increased-risk donors significantly more likely to have positive HBV, HCV screening results.
Physical activity was found to be associated with a reduced risk for hepatocellular carcinoma.
Much of the increase due to decrease in hepatitis C virus infection as indication for transplant.
Worker at Bauer’s Candies facility in Kentucky tested positive for hepatitis A.
Evidence convincing that universal prenatal screening reduces perinatal transmission of HBV.
More incident cases identified in intervention arm with nurse-led primary care-based liver clinics.
Investigators sought to determine the association between liver fibrosis and hepatitis B virus genotype G in patients with comorbid HIV and HBV.
The Advisory Committee on Immunization Practices Hepatitis Vaccines Work Group has updated recommendations for hepatitis A vaccination for PEP and PrEP.
Those with HCV genotype 1 with recent injection drug use and/or current opioid substitution therapy, paritaprevir/ritonavir, ombitasvir, and dasabuvir with/without ribavirin is effective.
Second study shows no significant difference in patients’ survival based on donor BMI.
Patients with chronic HCV undergoing short-term glecaprevir and pibrentasvir treatment show improved cardiovascular and metabolic extrahepatic manifestations.
Findings based on birth cohort, risk-based testing vs opt-out testing in prison system.
The Company has completed a first in human study in healthy volunteers; a Phase 2 trial in adults with NASH is due to begin soon in the US.
The approval was based on data from the KEYNOTE-224 study, a single-arm trial in patients with HCC who had disease progression on or after sorafenib or were intolerant to sorafenib; had measurable disease; and Child-Pugh class A liver impairment.
Adherence to the American Association for the Study of Liver Diseases criteria for evaluation and treatment of chronic HBV infection was found to be poor in all practice settings assessed.
Investigators aimed to determine rates and predictors of cirrhosis and cirrhosis-related complications in patients with chronic hepatitis B infection.